Table S7 Summary of Treatment-emergent Adverse Events

System Organ Class Preferred Term	Placebo (N=8) n (%)	nAE	ETC-1907206 10 mg Fasted (N=16) n (%)	nAE	10 mg Fed (N=9) n (%)	nAE	20 mg Fasted (N=14) n (%)	nAE
Subjects with at least one AE	5 (62.5)		9 (56.3)		9 (100)		11 (78.6)	
Subjects with no AE	3 (37.5)		7 (43.8)		0		3 (21.4)	
Gastrointestinal Disorders	0	0	4 (25.0)	7	2 (22.2)	3	3 (21.4)	5
Abdominal Distension	0	0	1 (6.3)	1	0	0	0	0
Diarrhoea	0	0	3 (18.8)	4	2 (22.2)	3	3 (21.4)	5
Toothache	0	0	1 (6.3)	1	0	0	0	0
Vomiting	0	0	1 (6.3)	1	0	0	0	0
General Disorders And Administration Site Conditions	0	0	2 (12.5)	2	2 (22.2)	2	0	0
Pyrexia	0	0	2 (12.5)	2	2 (22.2)	2	0	0
Infections And Infestations	0	0	1 (6.3)	1	0	0	0	0
Rhinitis	0	0	1 (6.3)	1	0	0	0	0
Injury, Poisoning And Procedural Complications	4 (50.0)	5	1 (6.3)	1	4 (44.4)	5	5 (35.7)	5
Arthropod Bite	0	0	0	0	0	0	1 (7.1)	1
Phlebitis	1 (12.5)	1	1 (6.3)	1	0	0	0	0
Post Procedural Complication	0	0	0	0	2 (22.2)	2	0	0
Post Procedural Discomfort	2 (25.0)	2	0	0	0	0	0	0
Procedural Pain	2 (25.0)	2	0	0	3 (33.3)	3	4 (28.6)	4

AE: Adverse event; n (%) = Number (percent) of subjects; nAE = Number of adverse events
Number of subjects in an analysis group is denominator for calculation of percentages.
AEs that occurred prior to a subject's first dose are not included.

Legend - ETC-1907206: ETC-206

Table S7 Summary of Treatment-emergent Adverse Events, continued

System Organ Class Preferred Term	Placebo (N=8) n (%)	nAE	ETC-1907206 10 mg Fasted (N=16) n (%)	nAE	10 mg Fed (N=9) n (%)	nAE	20 mg Fasted (N=14) n (%)	nAE
Investigations	0	0	5 (31.3)	7	1 (11.1)	1	1 (7.1)	2
Alanine Aminotransferase Increased	0	0	1 (6.3)	1	0	0	0	0
Blood Creatine Phosphokinase Increased	0	0	1 (6.3)	2	0	0	1 (7.1)	2
White Blood Cell Count Decreased	0	0	3 (18.8)	4	1 (11.1)	1	0	0
Metabolism And Nutrition Disorders	0	0	0	0	2 (22.2)	2	0	0
Hyperkalaemia	0	0	0	0	2 (22.2)	2	0	0
Nervous System Disorders	0	0	1 (6.3)	1	1 (11.1)	1	2 (14.3)	3
Headache	0	0	0	0	1 (11.1)	1	1 (7.1)	2
Lethargy	0	0	0	0	0	0	1 (7.1)	1
Seizure	0	0	1 (6.3)	1	0	0	0	0
Respiratory, Thoracic And Mediastinal Disorders	1 (12.5)	1	1 (6.3)	1	0	0	1 (7.1)	1
Cough	1 (12.5)	1	0	0	0	0	0	0
Oropharyngeal Pain	0	0	1 (6.3)	1	0	0	0	0
Rhinorrhoea	0	0	0	0	0	0	1 (7.1)	1
Skin And Subcutaneous Tissue Disorders	1 (12.5)	1	2 (12.5)	2	0	0	1 (7.1)	1
Rash	0	0	2 (12.5)	2	0	0	1 (7.1)	1
Rash Maculo-Papular	1 (12.5)	1	0	0	0	0	0	0

AE: Adverse event; n (%) = Number (percent) of subjects; nAE = Number of adverse events
Number of subjects in an analysis group is denominator for calculation of percentages.
AEs that occurred prior to a subject's first dose are not included.

Legend - ETC-1907206: ETC-206